Cordatus Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $323K | Buy |
2,570
+9
| +0.4% | +$1.13K | 0.08% | 137 |
|
|
2025
Q1 | $283K | Buy |
2,561
+84
| +3% | +$9.28K | 0.08% | 132 |
|
|
2024
Q4 | $338K | Buy |
2,477
+9
| +0.4% | +$1.23K | 0.09% | 123 |
|
|
2024
Q3 | $284K | Sell |
2,468
-9
| -0.4% | -$1.04K | 0.1% | 110 |
|
|
2024
Q2 | $341K | Sell |
2,477
-15
| -0.6% | -$2.07K | 0.13% | 101 |
|
|
2024
Q1 | $344K | Sell |
2,492
-21
| -0.8% | -$2.9K | 0.25% | 48 |
|
|
2023
Q4 | $331K | Sell |
2,513
-32
| -1% | -$4.22K | 0.27% | 43 |
|
|
2023
Q3 | $286K | Sell |
2,545
-51
| -2% | -$5.73K | 0.26% | 47 |
|
|
2023
Q2 | $245K | Buy |
+2,596
| New | +$245K | 0.09% | 133 |
|